Literature DB >> 26794505

Associations of Oral α-, β-, and γ-Human Papillomavirus Types With Risk of Incident Head and Neck Cancer.

Ilir Agalliu1, Susan Gapstur2, Zigui Chen3, Tao Wang1, Rebecca L Anderson2, Lauren Teras2, Aimée R Kreimer4, Richard B Hayes5, Neal D Freedman4, Robert D Burk6.   

Abstract

IMPORTANCE: Prospective studies are needed to examine the temporal relationship between oral human papillomavirus (HPV) detection and risk of head and neck squamous cell carcinoma (HNSCC). Moreover, the oral cavity contains a wide spectrum of α-, β-, and γ-HPV types, but their association with risk of HNSCC is unknown.
OBJECTIVE: To prospectively examine associations between α-, β-, and γ-HPV detection in the oral cavity and incident HNSCC.
DESIGN: A nested case-control study was carried out among 96 650 participants, cancer free at baseline, with available mouthwash samples in 2 prospective cohort studies: (1) the American Cancer Society Cancer Prevention Study II Nutrition Cohort and (2) the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Incident cases of HNSCC (n = 132) were identified during an average 3.9 years of follow-up in both cohorts. Three controls per case (n = 396) were selected through incidence density sampling and matched on age, sex, race/ethnicity, and time since mouthwash collection.
METHODS: Through a next-generation sequencing assay, DNA from α-, β-, and γ-HPV types were detected. Conditional logistic regression models were used to estimate odds ratios (ORs) and 95% CIs, adjusting for smoking history, alcohol consumption, and detection of HPV-16 for β- and γ-HPVs. MAIN OUTCOMES AND MEASURES: Incident HNSCC, which includes cancers of the oropharynx, oral cavity, and larynx.
RESULTS: A total of 132 participants developed HNSCC during the follow-up period (103 men and 29 women; average age at baseline, 66.5 years). Oral HPV-16 detection was associated with incident HNSCC (OR, 7.1; 95% CI, 2.2-22.6), with positive association for oropharyngeal SCC (OR, 22.4; 95% CI, 1.8-276.7), but not for oral cavity (OR, 4.5; 95% CI, 0.6-34.7) or laryngeal SCCs (OR, 0.11; 95% CI, 0.01-834.80). Detection of β1-HPV-5 and β2-HPV-38 types, as well as γ-11 and γ-12 species, had ORs for HNSCC that ranged from 2.64 to 5.45 (P < .01 for all comparisons). Detection of β1-HPV-5 type was associated with oropharyngeal (OR, 7.42; 95% CI, 0.98-56.82; P = .054), oral cavity (OR, 5.34; 95% CI, 1.51-18.80; P = .01), and laryngeal SCCs (OR, 2.71; 95% CI, 1.00-7.43; P = .05), whereas γ11- and γ12-HPV species were associated with both oral cavity (OR, 7.47; 95% CI, 1.21-46.17; P = .03; and OR, 6.71; 95% CI, 1.47-30.75; P = .01, respectively) and laryngeal SCCs (OR, 7.49; 95% CI, 1.10-51.04; P = .04 and OR, 5.31; 95% CI, 1.13-24.95; P = .03, respectively). CONCLUSIONS AND RELEVANCE: This study demonstrates that HPV-16 detection precedes the incidence of oropharyngeal SCC. Associations of other HPVs, including γ11- and γ12-HPV species and β1-HPV-5 type suggest a broader role for HPVs in HNSCC etiology.

Entities:  

Year:  2016        PMID: 26794505      PMCID: PMC4956584          DOI: 10.1001/jamaoncol.2015.5504

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


  42 in total

1.  The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics.

Authors:  Eugenia E Calle; Carmen Rodriguez; Eric J Jacobs; M Lyn Almon; Ann Chao; Marjorie L McCullough; Heather S Feigelson; Michael J Thun
Journal:  Cancer       Date:  2002-01-15       Impact factor: 6.860

Review 2.  Human papillomavirus and head and neck cancer: a systematic review and meta-analysis.

Authors:  C G L Hobbs; J A C Sterne; M Bailey; R S Heyderman; M A Birchall; S J Thomas
Journal:  Clin Otolaryngol       Date:  2006-08       Impact factor: 2.597

Review 3.  Role of human papillomavirus in the etiology of head and neck cancer.

Authors:  Nham Tran; Barbara R Rose; Christopher J O'Brien
Journal:  Head Neck       Date:  2007-01       Impact factor: 3.147

4.  Evidence for a causal association between human papillomavirus and a subset of head and neck cancers.

Authors:  M L Gillison; W M Koch; R B Capone; M Spafford; W H Westra; L Wu; M L Zahurak; R W Daniel; M Viglione; D E Symer; K V Shah; D Sidransky
Journal:  J Natl Cancer Inst       Date:  2000-05-03       Impact factor: 13.506

5.  Methods for etiologic and early marker investigations in the PLCO trial.

Authors:  Richard B Hayes; Alice Sigurdson; Lee Moore; Ulrike Peters; Wen-Yi Huang; Paul Pinsky; Douglas Reding; Edward P Gelmann; Nat Rothman; Ruth M Pfeiffer; Robert N Hoover; Christine D Berg
Journal:  Mutat Res       Date:  2005-07-27       Impact factor: 2.433

6.  Comparisons of HPV DNA detection by MY09/11 PCR methods.

Authors:  Philip E Castle; Mark Schiffman; Patti E Gravitt; Hortense Kendall; Stacy Fishman; Huali Dong; Allan Hildesheim; Rolando Herrero; M Concepcion Bratti; Mark E Sherman; Attila Lorincz; John E Schussler; Robert D Burk
Journal:  J Med Virol       Date:  2002-11       Impact factor: 2.327

7.  Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study.

Authors:  Rolando Herrero; Xavier Castellsagué; Michael Pawlita; Jolanta Lissowska; Frank Kee; Prabda Balaram; Thangarajan Rajkumar; Hema Sridhar; Barbara Rose; Javier Pintos; Leticia Fernández; Ali Idris; María José Sánchez; Adoración Nieto; Renato Talamini; Alessandra Tavani; F Xavier Bosch; Ulrich Reidel; Peter J F Snijders; Chris J L M Meijer; Raphael Viscidi; Nubia Muñoz; Silvia Franceschi
Journal:  J Natl Cancer Inst       Date:  2003-12-03       Impact factor: 13.506

8.  Case-control study of human papillomavirus and oropharyngeal cancer.

Authors:  Gypsyamber D'Souza; Aimee R Kreimer; Raphael Viscidi; Michael Pawlita; Carole Fakhry; Wayne M Koch; William H Westra; Maura L Gillison
Journal:  N Engl J Med       Date:  2007-05-10       Impact factor: 91.245

9.  Human papillomavirus infection and oral cancer: a case-control study in Montreal, Canada.

Authors:  Javier Pintos; Martin J Black; Nader Sadeghi; Parviz Ghadirian; Anthony G Zeitouni; Raphael P Viscidi; Rolando Herrero; François Coutlée; Eduardo L Franco
Journal:  Oral Oncol       Date:  2007-04-27       Impact factor: 5.337

10.  Human papillomavirus in oral exfoliated cells and risk of head and neck cancer.

Authors:  Elaine M Smith; Justine M Ritchie; Kurt F Summersgill; Henry T Hoffman; Dong Hong Wang; Thomas H Haugen; Lubomir P Turek
Journal:  J Natl Cancer Inst       Date:  2004-03-17       Impact factor: 13.506

View more
  53 in total

1.  Evaluating the Utility and Prevalence of HPV Biomarkers in Oral Rinses and Serology for HPV-related Oropharyngeal Cancer.

Authors:  Gypsyamber D'Souza; Gwendolyn Clemens; Tanya Troy; Rachel G Castillo; Linda Struijk; Tim Waterboer; Noemi Bender; Phillip M Pierorazio; Simon R Best; Howard Strickler; Dorothy J Wiley; Robert I Haddad; Marshall Posner; Carole Fakhry
Journal:  Cancer Prev Res (Phila)       Date:  2019-08-16

2.  Diversity of beta-papillomavirus at anogenital and oral anatomic sites of men: The HIM Study.

Authors:  Emily Montosa Nunes; Staci L Sudenga; Tarik Gheit; Massimo Tommasino; Maria Luiza Baggio; Silvaneide Ferreira; Lenice Galan; Roberto C Silva; Christine M Pierce Campbell; Eduardo Lazcano-Ponce; Anna R Giuliano; Luisa L Villa; Laura Sichero
Journal:  Virology       Date:  2016-05-07       Impact factor: 3.616

3.  The Natural History of Oral Human Papillomavirus in Young Costa Rican Women.

Authors:  Daniel C Beachler; Krystle A Lang Kuhs; Linda Struijk; John Schussler; Rolando Herrero; Carolina Porras; Allan Hildesheim; Bernal Cortes; Joshua Sampson; Wim Quint; Paula Gonzalez; Aimée R Kreimer
Journal:  Sex Transm Dis       Date:  2017-07       Impact factor: 2.830

Review 4.  Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention.

Authors:  Ana Gradíssimo; Robert D Burk
Journal:  Expert Rev Mol Diagn       Date:  2017-02-20       Impact factor: 5.225

Review 5.  The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer.

Authors:  Theresa Guo; David W Eisele; Carole Fakhry
Journal:  Cancer       Date:  2016-05-06       Impact factor: 6.860

6.  Quantitative Oral HPV16 and HPV18 Detection in Persons Attending Dental Clinics.

Authors:  Helen C Stankiewicz Karita; Amalia Magaret; Meei-Li Huang; Keith R Jerome; Quinne Feng; Anna Wald
Journal:  Sex Transm Dis       Date:  2020-02       Impact factor: 2.830

7.  Cervical Infection with Cutaneous Beta and Mucosal Alpha Papillomaviruses.

Authors:  Laura Sichero; Mariam El-Zein; Emily M Nunes; Silvaneide Ferreira; Eduardo L Franco; Luisa L Villa
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-04-04       Impact factor: 4.254

8.  Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment.

Authors:  Yuehan Zhang; Tim Waterboer; Robert I Haddad; Brett A Miles; Alicia Wentz; Neil D Gross; Carole Fakhry; Harry Quon; Jochen H Lorch; Christine G Gourin; Daniel Clayburgh; Krzysztof J Misiukiewicz; Jeremy D Richmon; Peter E Andersen; Marshall R Posner; Gypsyamber D'Souza
Journal:  Oral Oncol       Date:  2017-02-15       Impact factor: 5.337

9.  Unique role of HPV16 in predicting oropharyngeal cancer risk more than other oncogenic oral HPV infections.

Authors:  Carole Fakhry; Nicholas Fung; Sakshi R Tewari; Gypsyamber D'Souza
Journal:  Oral Oncol       Date:  2020-08-29       Impact factor: 5.337

10.  Oral Alpha, Beta, and Gamma HPV Types and Risk of Incident Esophageal Cancer.

Authors:  Ilir Agalliu; Zigui Chen; Tao Wang; Richard B Hayes; Neal D Freedman; Susan M Gapstur; Robert D Burk
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-08-07       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.